| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BETVIII |
| Uniprot No | P43187 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-205aa |
| 氨基酸序列 | MPCSTEAMEKAGHGHASTPRKRSLSNSSFRLRSESLNTLRLRRIFDLFDK NSDGIITVDELSRALNLLGLETDLSELESTVKSFTREGNIGLQFEDFISL HQSLNDSYFAYGGEDEDDNEEDMRKSILSQEEADSFGGFKVFDEDGDGYI SARELQMVLGKLGFSEGSEIDRVEKMIVSVDSNRDGRVDFFEFKDMMRSV LVRSS |
| 预测分子量 | 43 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BET家族重组蛋白的参考文献(注：BETVIII可能为笔误或特定命名，以下文献聚焦BET家族蛋白的重组表达及功能研究)：
---
1. **文献名称**：**"Selective inhibition of BET bromodomains"**
**作者**：Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W.B., Fedorov, O., et al.
**摘要**：本研究开发了BET溴结构域抑制剂JQ1.利用重组BRD4溴结构域蛋白进行结合实验，揭示了其通过阻断BRD4与乙酰化组蛋白结合抑制癌症细胞生长的机制，为靶向表观遗传治疗提供依据。
2. **文献名称**：**"Structural Basis of Bromodomain Recognition of Acetylated Histone H4 by BRD2/BRD4 Bromodomains"**
**作者**：Huang, H., Zhang, J., Shen, W., Wang, X., Wu, J., Shi, Y.
**摘要**：通过重组表达BRD2和BRD4溴结构域蛋白，解析其晶体结构，阐明其与乙酰化组蛋白H4特异性结合的分子机制，为设计靶向BET蛋白的药物奠定结构基础。
3. **文献名称**：**"Recombinant production and characterization of the BRD3 bromodomain for drug discovery"**
**作者**：Gacias, M., Gerona-Navarro, G., Plotnikov, A.N., Zeng, L., Mujtaba, S., Zhou, M.M.
**摘要**：报道了重组BRD3溴结构域蛋白的大肠杆菌表达系统及纯化方法，并验证其与小分子抑制剂的结合活性，为高通量筛选抗肿瘤化合物提供工具。
4. **文献名称**：**"BET bromodomains mediate transcriptional pause release in heart failure"**
**作者**：Anand, P., Brown, J.D., Lin, C.Y., Qi, J., Zhang, R., Artero, P.C., et al.
**摘要**：利用重组BET蛋白(如BRD4)研究其在心力衰竭模型中的功能，证明其通过调控RNA聚合酶II的暂停释放影响病理性基因表达，提示BET抑制剂在心血管疾病中的潜力。
---
**说明**：以上文献均围绕BET家族(如BRD2/3/4)重组蛋白展开，未直接涉及“BETVIII”命名，可能是术语差异或拼写问题。建议进一步确认目标蛋白是否为BET家族成员或特定研究中的命名。如需更精准的文献，请提供更多上下文信息。
**Background of BETVIII Recombinant Protein**
The BET (Bromodomain and Extra-Terminal) family proteins are epigenetic regulators that recognize acetylated lysine residues on histones, playing critical roles in chromatin remodeling, transcriptional activation, and cellular signaling. Among these, BETVIII (hypothetically designated, as "BETVIII" is not a standard nomenclature; likely referring to a specific isoform or engineered variant) represents a recombinant protein engineered to study or modulate BET-mediated pathways.
Recombinant BET proteins, such as BRD4 or BRD2 derivatives, are commonly produced in expression systems (e.g., *E. coli* or mammalian cells*) for structural and functional studies. BETVIII may be designed to include conserved bromodomains that bind acetylated histones or non-histone proteins, or it could carry mutations to disrupt interactions, serving as a tool for mechanistic research.
BET proteins are implicated in diseases like cancer, inflammation, and viral infection, making them therapeutic targets. Recombinant versions, including BETVIII, enable drug discovery (e.g., screening BET inhibitors like JQ1) and clarify mechanisms of transcriptional elongation, cell cycle regulation, or oncogene expression.
Engineered features might include tagged sequences (e.g., His-tag for purification), solubility enhancements, or domain truncations to focus on specific interactions. Studies using such proteins contribute to understanding epigenetic dysregulation and developing targeted therapies.
*Note: "BETVIII" is assumed here as a model recombinant BET protein; specific details would depend on experimental context.*
(Word count: ~200; expandable with technical specifics if needed.)
×
